FY2025 · ended Dec 31, 2025 · Revenue $638.50M, +65.5% YoY · Filed Feb 23, 2026
Axsome Therapeutics, Inc. (AXSM) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $638.5 million and a net loss of $183.2 million. Free cash flow was -$93.9 million. As of Sep 30, 2026 it held $313.9 million in cash and investments and $224.2 million in total debt.
Revenue (TTM)
$865.27M
+54.2% vs year-ago TTM
Net income (TTM)
$-157.29M
+31.5% vs year-ago TTM
Operating cash flow (TTM)
$-81.77M
+19.0% vs year-ago TTM
Free cash flow (TTM)
$-82.61M
+18.5% vs year-ago TTM
EPS (TTM)
$-3.05
+34.5% vs year-ago TTM
Dividend per share
None
Shares outstanding
51.15M
+4.9% vs prior year
Net cash
$89.63M
as of Sep 30, 2026
Operating margin
-17.5%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AXSM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1579428
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $638.5M | $385.7M | $270.6M | $50.0M | — |
| Operating income | -$166.8M | -$280.6M | -$231.8M | -$179.8M | -$124.7M |
| Net income | -$183.2M | -$287.2M | -$239.2M | -$187.1M | -$130.4M |
| Diluted EPS | -$3.68 | -$5.99 | -$5.27 | -$4.60 | — |
| Operating cash flow | -$93.4M | -$128.4M | -$145.1M | -$116.5M | -$108.2M |
| Free cash flow | -$93.9M | -$128.7M | -$145.7M | -$117.2M | -$108.5M |
| Total assets | $689.8M | $568.5M | $588.2M | $331.5M | $87.8M |
| Total liabilities | $601.5M | $511.5M | $397.3M | $221.9M | $72.2M |
| Stockholders' equity | $88.3M | $57.0M | $191.0M | $109.6M | $15.6M |
| Cash and investments | $322.9M | $315.4M | $386.2M | $200.8M | $86.5M |
| Total debt | $218.1M | $193.0M | $186.4M | $94.7M | $49.7M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Nov 2, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Nov 2, 2026 | Nov 2, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Other events
|
Aug 10, 2026 | Aug 10, 2026 |
| 8-K |
Current report
Other events
|
Jul 15, 2026 | Jul 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Jun 9, 2026 | Jun 5, 2026 |
All 672 Axsome Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.